US10149841B2 - Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof - Google Patents

Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof Download PDF

Info

Publication number
US10149841B2
US10149841B2 US15/561,435 US201515561435A US10149841B2 US 10149841 B2 US10149841 B2 US 10149841B2 US 201515561435 A US201515561435 A US 201515561435A US 10149841 B2 US10149841 B2 US 10149841B2
Authority
US
United States
Prior art keywords
compound
pharmaceutically acceptable
subject
acceptable salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/561,435
Other languages
English (en)
Other versions
US20180117021A1 (en
Inventor
Yunlong Zhou
Suixiong Cai
GuangFeng Wang
Lingling JIAO
Ping MIN
Yu Jing
Ming Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Sunshine Pharmaceutical Co Ltd
Original Assignee
Shenyang Sunshine Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Sunshine Pharmaceutical Co Ltd filed Critical Shenyang Sunshine Pharmaceutical Co Ltd
Assigned to SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. reassignment SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAI, SUIXIONG, GUO, MING, JIAO, Lingling, JING, YU, MIN, Ping, WANG, GUANGFENG, ZHOU, YUNLONG
Publication of US20180117021A1 publication Critical patent/US20180117021A1/en
Application granted granted Critical
Publication of US10149841B2 publication Critical patent/US10149841B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to the field of medicine, and particularly the present invention relates to a 3-hydroxyl compound, a preparation method of the compound and a use thereof for the preparation of a medicament for inhibiting the activity of hypoxiainducible factor (HIF) prolyl hydroxylase.
  • HIF hypoxiainducible factor
  • Hypoxia inducible factor is a section of transcriptional activator containing basic helix-loop-helix (bHLH) and PAS (Per/Arnt/Sim) that responds to the hypoxia conditions by mediating a series of gene regulation in biological cells.
  • bHLH basic helix-loop-helix
  • PAS Per/Arnt/Sim
  • HIF Hypoxia Inducible Factor
  • HIF consists of two subunits, HIF-a and HIF-b.
  • HIF-a contains an oxygen-dependent degradation domain (abbreviated as ODDD), which is a key element unit in response to cellular oxygen content.
  • ODDD oxygen-dependent degradation domain
  • HIF-a can form a stable dimer with HIF-b. After this dimer enters the nucleus, it activates the expression of important enzymes or enzyme systems such as glucose metabolism-related enzymes, GLUT-1, erythropoietin and vascular endothelial growth factor (VEGF), and thus resists the cell hypoxia conditions.
  • HIF-b is a type of aryl hydrocarbon nuclear translator (abbreviated as ARNT), which forms a heterodimer with HIF-a to activate transcription of downstream genes.
  • ARNT aryl hydrocarbon nuclear translator
  • HIF-1a HIF-1a
  • HIF-2a HIF-2a
  • HIF-3a HIF-1a
  • HIF-1a first discovered by Wang in 1995, is widely expressed in human and mouse bodies.
  • HIF-2a was isolated and identified in 1997, which has a protein sequence with 48% similarity to that of HIF-1a and therefore has the similar functions to HIF-1a, however, HIF-2a is only expressed in lung, endothelium and carotid artery.
  • HIF-3a is a newly discovered HIF-a subtype, and little research has been done on it yet.
  • HIF-a in cells having normal oxygen content, but HIF-a cannot stably exist in the cells having normal oxygen content, and has a half-life of only 5 minutes. HIF-a can only be stable under hypoxic conditions and thus play the normal function of activation of downstream transcription factors.
  • the prolyl at positions 402,564 in the ODDD region of HIF-a was oxidized by prolyl hydroxylase to form 4-hydroxyprolyl, so that HIF-a cannot be dimmed with HIF-b, but soon binds to pVHL protein and then be degraded, and therefore cannot play an anti-hypoxia function.
  • Prolyl hydroxylase (also abbreviated as PHD or EGLN), which plays a key role in the degradation of HIF-a, is a 2-oxoglutatone (2-OG)-dependent oxygenase.
  • 2-OG and divalent iron ions as prosthetic groups, PHD transfers an oxygen atom to the 4-position of the prolyl molecule to form a hydroxyprolyl, and meanwhile converts 2-OG into one carbon dioxide molecule and succinic acid.
  • Both 2-OG analogs and divalent nickel, cobalt and manganese ions can antagonize the oxidation of prolyl in HIF-a by PHD, and inhibit the degradation of HIF-a, so that HIF-a can successfully be dimmed with HIF-b, and thus stimulates the downstream transcription factors, and ultimately plays an anti-hypoxia function.
  • PHD has three subtypes: PHD1, PHD2, and PHD3. Further studies suggest that inhibition on PHD1 can help to treat skeletal muscle cell degradation, can protect myofibroblasts under ischemic conditions, treat inflammatory enteritis and colitis, and treat heart failure and ischemia in patients with heart disease and kidney disease. However, no study has shown that the other two PHD subtypes have difference in functions.
  • EPO erythropoietin
  • EPO erythropoietin
  • red blood cell proliferation As a glycoprotein hormone, EPO can stimulate red blood cell proliferation, differentiation and maturation. EPO on the one hand can stimulate bone marrow hematopoietic function, timely and effectively increase the number of red blood cells, thereby enhancing the oxygen carrying capacity of the blood.
  • EPO can enhance the body's oxygen binding, transport and supply capacity, and improve hypoxia conditions. Under normal physiological conditions, EPO is mainly synthesized and secreted by the kidney, therefore, a patient with kidney failure will suffer from ischemia because EPO cannot be normally synthesized in the body.
  • EPO EPO is expensive, and is a great burden especially for the patients who need long-term use.
  • EPO also has the characteristics of low bioavailability, short half-life in the organism, easy to be hydrolyzed by the enzyme in the gastrointestinal tract, so EPO must be frequently administrated by injection, which limits the probability of patient's self-administration, and brings great inconvenience to the patients.
  • Industrially synthetic EPO still cannot avoid the immunogenicity and the product has certain medication risks.
  • R 1 , R 2 are each independently hydrogen.
  • R 3 is selected from the group consisting of hydrogen, a C 1 -C 7 straight-chain, and a branched or cyclic alkyl;
  • R 4 , R 5 , R 6 , R 7 , and R 8 are each independently selected from C 1 -C 7 alkyl, halo C 1 -C 7 alkyl, C 1-3 alkoxy, halo C 1-3 alkoxy, halogen, hydroxy, hydrogen, amino, nitro, cyano and substituted or unsubstituted aromatic ring or an heteroaromatic ring.
  • R 4 , R 5 , R 6 , R 7 , and R 8 are each independently selected from C 1 -C 7 alkyl, halo C 1 -C 7 alkyl, C 1-3 alkoxy, halo C 1-3 alkoxy, halogen, hydroxy, hydrogen, amino, nitro, cyano and substituted or unsubstituted aromatic ring or an heteroaromatic ring.
  • R 4 , R 5 , R 6 , R 7 , and R 8 are each independently selected from C 1 -C 7 alkyl, halo C 1 -C 7 al
  • R 4 , R 5 , R 6 , R 7 , R 8 are bonded to each other with an oxygen bridge to form a compound having the following structural formula (II) or a pharmaceutically acceptable salt thereof:
  • n is an integer of 1, 2, 3 or 4;
  • a 1 and A 2 are each independently an oxygen, carbon or nitrogen atom.
  • the pharmaceutically acceptable salt of the compound of Formula (I) and (II) is preferably formed by reacting the compound with a pharmaceutically acceptable base.
  • the pharmaceutically acceptable bases include, but are not limited to, sodium hydroxide, sodium carbonate, potassium hydroxide, potassium carbonate, magnesium hydroxide, magnesium oxide, calcium hydroxide, calcium oxide and the like.
  • the preferred compound of the present invention is selected from the group consisting of the following compounds:
  • the method for preparing a compound of the present invention comprises the following steps:
  • step 1 reacting 5-bromo-3-fluoropyridyl-2-carbonitrile
  • step 2 mixing and heating the intermediate (III) obtained in the step 1 with ArOH and a ligand in a solvent, and subjecting to an Ullman reaction in the participation of a catalyst to form an ether intermediate (IV),
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from C 1 -C 7 alkyl, halo C 1 -C 7 alkyl, C 1 -C 3 alkoxy, halo C 1 -C 3 alkoxy, halogen, hydroxy, hydrogen, amino, nitro, cyano, substituted or unsubstituted aromatic ring or heteroaromatic ring;
  • step 3 subjecting the intermediate (IV) obtained in the step 2 and HBr to hydrolysis reaction under reflux, to form a 3-hydroxypyridine-2-methanoic acid derivative (V)
  • step 4 subjecting the intermediate (V) obtained in the step 3 and ⁇ -R 3 -substituted amino acid benzyl ester (VI) to an amidation reaction in the presence of a condensing agent, to form a benzyl 3-hydroxypyridine-2-carboxylate intermediate (VII);
  • step 5 subjecting the intermediate (VII) obtained in the step 4 to hydrogenolysis reaction under hydrogenolysis condition in a solvent in the presence of a catalyst at room temperature to remove the benzyl protecting group, to finally form a compound corresponding to Formula I.
  • the starting material 5-bromo-3-fluoropyridine-2-carbonitrile can be obtained by a commercial route, for example, purchased from sigma or J & K.
  • the reaction is carried out at room temperature.
  • the catalyst in the above step 2 is preferably cuprous (I) iodide.
  • Preferred metal ligands include N, N-dimethylglycine, N-methylproline, N, N-tetramethylethylenediamine and the like.
  • Preferred reaction solvents include 1,4-dioxane, toluene, and tetrahydrofuran.
  • the reaction is carried out by heating to 70° C. to 120° C.
  • the step 3 comprises subjecting the intermediate (IV) to deprotection and meanwhile hydrolysis reaction in hydrobromic acid/glacial acetic acid to obtain 3-hydroxypyridine-2-methanoic acid intermediate (V).
  • Preferred ratio of hydrobromic acid to glacial acetic acid is 2:1 ⁇ 1:3.
  • Preferred reaction temperature is 90-140° C.
  • Preferred heating reaction time is 6 ⁇ 12 hours.
  • the ⁇ -R 3 amino acid benzyl ester (VI) may be in its hydrochloride form.
  • the amino acid ⁇ -R 3 benzyl ester hydrochloride may be selected from the group consisting of glycine benzyl ester hydrochloride, ( ⁇ or ⁇ ) alanine benzyl ester hydrochloride, ( ⁇ or ⁇ ) valine benzyl ester hydrochloride, ( ⁇ or ⁇ ) leucine benzyl ester hydrochloride, ( ⁇ or ⁇ ) isoleucine benzyl ester hydrochloride and the like.
  • Preferred solvents include dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, N-methylpyrrolidone and the like.
  • Preferred amidation catalysts include 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), I-hydroxybenzotriazole (HOBT), dicyclohexylcarbodiimide (DCC) and the like.
  • Preferred bases include triethylamine, and N, N-diisopropylethylamine.
  • the reaction is carried out by mixing and stirring the intermediate (V) with the amino acid benzyl ester hydrochloride (VI) and the condensing agent at room temperature for more than 10 hours.
  • preferred catalysts include palladium (0) /carbon, palladium (II) hydroxide, palladium (II) hydroxide/carbon, platinum (IV) dioxide and the like.
  • the solvent for hydrogenolysis preferably include methanol, ethanol, isopropanol, tetrahydrofuran, ethyl acetate and the like.
  • the present invention also relates to a use of the compound of the invention or a pharmaceutically acceptable salt thereof in the preparation of a medicament for inhibiting HIF prolyl hydroxylase; a use of the compound of the invention in the preparation of a medicament for promoting the generation of endogenous EPO; a use of the compound of the invention in the preparation of a medicament for stabilizing hypoxia-inducible factor ⁇ ; a use of the compound of the invention in the preparation of a medicament for treating chronic disease-related anemia in a subject, wherein the chronic disease-related anemia is selected from the group consisting of rheumatoid arthritis, rheumatic fever and inflammatory bowel disease; a use of the compound of the invention in the preparation of a medicament for increasing the production of inflammatory cytokines in a subject, wherein the inflammatory cytokines include tumor necrosis factor, interleukin and interferon; a use of the compound of the invention in the preparation of a medicament for treating anemia in a subject that is resistant to
  • the present invention also relates to a method for inhibiting HIF prolyl hydroxylase in a subject comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof; to a method for promoting the generation of endogenous EPO in a subject comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof; to a method for stabilizing hypoxia-inducible factor ⁇ in a subject comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof; to a method for treating chronic disease-related anemia in a subject comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof, wherein the chronic disease-related anemia is selected from the group consisting of rheumatoid arthritis, rheumatic fever and inflammatory bowel disease.
  • the present invention also relates to a method for increasing the production of inflammatory cytokines in a subject comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof, wherein the inflammatory cytokines include tumor necrosis factor, interleukin and interferon.
  • a further aspect of the present invention relates to a method for treating anemia in a subject that is resistant to the treatment of exogenous erythropoietin administration comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof, wherein the compound enhances the response of hematopoietic precursor cells to the erythropoietin.
  • the present invention also relates to a method for increasing the production of a factor required for iron ingestion, iron transport and iron utilization in a subject comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof, wherein the factor is selected from the group consisting of erythrocyte aminolevulinic acid synthase, transferrin, transferrin receptor and plasma ceruloplasmin.
  • 3-methoxy-5-phenoxypyridine-2-carbonitrile 600 mg was dissolved in glacial acetic acid (15 ml), added with hydrobromic acid solution (15 ml) and reacted at 120° C. for 8 hours. The reaction solution was cooled to 25° C. and allowed to stand for 8 hours to precipitate a solid. The solid was filtered and the filter cake was washed with water, collected and dried under reduced pressure to obtain 3-hydroxy-5-phenoxypyridine-2-methanoic acid as a white solid (370 mg, yield 60%).
  • Step 4 Preparation of benzyl 2-(3-hydroxy-5-phenoxypyridine-2-formamido) acetate
  • reaction solution was concentrated and partitioned between ethyl acetate (50 ml) and water (30 ml).
  • the ethyl acetate layer was concentrated and subjected to column chromatography to obtain 410 mg of 5-(2,3-dimethylphenoxy)-3-methoxy-pyridine-2-carbonitrile as a pale yellow solid, 80.7%.
  • Step 4 Preparation of benzyl ⁇ [5-(2,3-dimethylphenoxy)-3-hydroxy-pyridine-2-carbonyl]-amino ⁇ -acetate
  • Step 5 Preparation of 2-(5-(2,3-dimethylphenoxy)-3-hydroxypyridine-2-formamido) acetic acid
  • Step 4 Preparation of benzyl ⁇ [5-(3-chlorophenoxy)-3-hydroxy-pyridine-2-carbonyl]-amino ⁇ -acetate
  • Step 5 Preparation of 2-(5-(3-chlorophenoxy)-3-hydroxypyridine-2-formamido) acetic acid
  • reaction solution was concentrated and partitioned between ethyl acetate (50 ml) and water (30 ml).
  • the ethyl acetate layer was concentrated and subjected to column chromatography to obtain 300 mg of 3-methoxy-5-(naphthalen-2-oxo)-pyridine-2-carbonitrile as a red solid, 72.5%.
  • Step 4 Preparation of benzyl ⁇ [3-hydroxy-5-(naphthalen-2-oxo)-pyridine-2-carbonyl]-amino ⁇ -acetate
  • Step 5 Preparation of 2-(3-hydroxy-5-(naphthalen-2-oxo) pyridine-2-formamido) acetic acid
  • reaction solution was concentrated and partitioned between ethyl acetate (50 ml) and water (30 ml).
  • the ethyl acetate layer was concentrated and subjected to column chromatography to obtain 250 mg of 5-(2,4-dimethylphenoxy)-3-methoxy-pyridine-2-carbonitrile as a pale yellow solid, 49.2%.
  • Step 4 Preparation of benzyl ⁇ [5-(2,4-dimethylphenoxy)-3-hydroxy-pyridine-2-carbonyl]-amino ⁇ -acetate
  • Step 5 Preparation of 2-(5-(2,4-dimethylphenoxy)-3-hydroxypyridine-2-formamido) acetic acid
  • reaction solution was concentrated and partitioned between ethyl acetate (50 ml) and water (30 ml).
  • the ethyl acetate layer was concentrated and subjected to column chromatography to obtain 160 mg of 5-(2,3-difluoro-phenoxy)-3-methoxy-pyridine-2-carbonitrile as a pale yellow solid, 30.5%.
  • Step 4 Preparation of benzyl ⁇ [5-(2,3-difluoro-phenoxy)-3-hydroxy-pyridine-2-carbonyl]-amino ⁇ -acetate
  • Step 5 Preparation of 2-(5-(2,3-difluorophenoxy)-3-hydroxypyridine-2-formamido) acetic acid
  • the ELISA kit was purchased from Quantikine IVD ELISA, Human Erythropoietin (R&D, DEP00).
  • the test control AKB-6548 was prepared by the inventors or obtained by commercial purchase. The test substance was stored at ⁇ 20° C. in the dark.
  • test substance and the positive control substance were fully dissolved in sterile water or dimethylsulfoxide under dark conditions and prepared into a stock solution at a concentration of 10 ⁇ 1 mol/L or 10 ⁇ 2 mol/L. Each of the stock solutions was stored at ⁇ 20° C. MEM medium containing 0.5% FBS was used as a diluent to dilute the stock solution of the test substance, to prepare a diluted test substance at a concentration of 100 ⁇ mol/L and 10 ⁇ mol/L. 200 ⁇ l/well (1.5 or 2.0 ⁇ 10 4 cells/well) of hepatoma cells Hep3B complete medium suspension was added to a 96-well culture plate and incubated overnight at 37° C. in a 5% CO 2 incubator.
  • the solution in the 96-well culture plate was removed and the cells were washed once with the MEM medium containing 0.5% FBS. 200 ⁇ l/well of the test substance was added in the dark, at a dose of 100 ⁇ mol/L and 10 ⁇ mol/L, and each dose set 2 wells, a test well and a spare well.
  • a cell control well was prepared by replacing the test solution with the diluent (without test substance and solvent).
  • a solvent control well was prepared by replacing the test solution with the diluent containing the corresponding concentration of solvent (dimethylsulfoxide) (without test substance). They were cultured in a 5% CO 2 incubator at 37° C. for 24 hours.
  • the supernatant was absorbed as a sample and cryopreserved at ⁇ 20° C. for later use. 100 ⁇ l/well of stop solution was added. OD value was detected by microplate reader A450 nm-A600 nm.
  • the expression level of EPO (mIU/mL) promoted by the test substance was obtained according to the standard curve, and then the ratio of EPO expression content of the test substance to the EPO expression content of the positive control AKB6548 was calculated.
  • the test results are shown in the following table:
  • EPO level/ EPO level/ AKB6548 AKB6548 EPO level EPO level Compound (10 ⁇ M) Compound (10 ⁇ M) 1 0.5 33 0.2 12 0.8 27 0.0 2 0.3 34 0.5 13 0.5 28 0.1 14 1.7 35 0.2 16 1.1 29 0.2 6 0.6 30 1.0 4 1.5 20 1.4 3 0.8 31 0.1 5 1.3 25 0.2 18 1.3 26 0.6 8 1.5 32 0.8 17 1.2 9 1.5 7 0.2 10 0.6 21 1.5 19 1.3
  • hypoxia-inducible factor HIF-1 ⁇ and VBC complex (von Hippel-Lindau protein-Elongin B-Elongin C, VBC) was detected by Fluorescence polarization (FP) method, to measure the enzyme inhibitory activity of the HIF Prolyl hydroxylases 2 (PHD2) inhibitor compounds.
  • FP Fluorescence polarization
  • EBC buffer 50 mM Tris.HCl, 120 mM NaCl, 0.5% NP-40
  • a GST-VBC complex was added to the corresponding test wells at a final concentration of 300 nM (using the wells containing only EBC buffer as blank wells).
  • the corresponding PHD2 prolyl hydroxylation reaction sample was added in the dark as a substrate with a final concentration of 100 nM.
  • the lateral and longitudinal fluorescence intensity values were measured using a full-wavelength multifunctional microplate reader (TECAN infinite M1000) at an excitation wavelength of 407 nm and an emission wavelength of 518 nm.
  • mP fluorescence polarization
  • lateral value lateral fluorescence intensity value of test well ⁇ lateral fluorescence intensity value of blank well
  • the IC 50 was calculated using the non-linear regression data analysis method of Graphpad Prism 4.0 software (Golden software, Golden, Colo., USA).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US15/561,435 2015-03-27 2015-12-14 Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof Active US10149841B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201510141553.3A CN106146395B (zh) 2015-03-27 2015-03-27 3-羟基吡啶化合物、其制备方法及其制药用途
CN201510141553.3 2015-03-27
CN201510141553 2015-03-27
PCT/CN2015/097246 WO2016155359A1 (zh) 2015-03-27 2015-12-14 3-羟基吡啶化合物、其制备方法及其制药用途

Publications (2)

Publication Number Publication Date
US20180117021A1 US20180117021A1 (en) 2018-05-03
US10149841B2 true US10149841B2 (en) 2018-12-11

Family

ID=57006497

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/561,435 Active US10149841B2 (en) 2015-03-27 2015-12-14 Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof

Country Status (5)

Country Link
US (1) US10149841B2 (de)
EP (1) EP3275864B1 (de)
JP (1) JP6473519B2 (de)
CN (1) CN106146395B (de)
WO (1) WO2016155359A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920108A (zh) * 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
KR20210078518A (ko) * 2018-10-18 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조직 거주 기억-유사 t 세포의 생산 방법 및 이의 용도
TW202220961A (zh) * 2020-08-14 2022-06-01 美商阿克比治療有限公司 Ｐｈｄ抑制劑化合物、組成物及使用方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254215A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
US20070298104A1 (en) 2006-01-27 2007-12-27 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
US20070299086A1 (en) 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
US20090082357A1 (en) 2006-03-07 2009-03-26 Fitch Duke M Prolyl Hydroxylase Inhibitors
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
US20100113444A1 (en) 2006-06-23 2010-05-06 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US20100305097A1 (en) 2002-11-09 2010-12-02 Namal Chithranga Warshakoon N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones
US20110263644A1 (en) 2006-02-16 2011-10-27 Fibrogen, Inc. Compounds and Methods for Treatment of Stroke
US20120309977A1 (en) 2011-06-06 2012-12-06 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
US20140343089A1 (en) 2011-11-22 2014-11-20 Beijing Medisn Technology Co., Ltd. Norepinephrine and selective serotonin receptor blocker and use thereof
US20150038528A1 (en) 2012-03-09 2015-02-05 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
ES2101420T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650961B1 (de) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) * 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN102552263A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
AR055319A1 (es) * 2005-03-17 2007-08-15 Wyeth Corp Derivados de isoquinoleina, composiciones farmaceuticas y usos
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
WO2008040002A2 (en) * 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
CN103608346B (zh) * 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305097A1 (en) 2002-11-09 2010-12-02 Namal Chithranga Warshakoon N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones
US20080293763A1 (en) 2003-06-06 2008-11-27 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
US20040254215A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
US20070298104A1 (en) 2006-01-27 2007-12-27 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
US20110263644A1 (en) 2006-02-16 2011-10-27 Fibrogen, Inc. Compounds and Methods for Treatment of Stroke
US20090082357A1 (en) 2006-03-07 2009-03-26 Fitch Duke M Prolyl Hydroxylase Inhibitors
US20100113444A1 (en) 2006-06-23 2010-05-06 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20100331374A1 (en) 2006-06-26 2010-12-30 Shengde Wu Prolyl hydroxylase inhibitors and methods of use
US20070299086A1 (en) 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US20120309977A1 (en) 2011-06-06 2012-12-06 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
US20140343089A1 (en) 2011-11-22 2014-11-20 Beijing Medisn Technology Co., Ltd. Norepinephrine and selective serotonin receptor blocker and use thereof
US20150038528A1 (en) 2012-03-09 2015-02-05 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chowdhury et al., "The Human Oxygen Sensing Machinery and its Manipulation," Chemical Society Reviews (2008), 37(7), pp. 1308-1319.
International Search Report from International Patent Application No. PCT/CN2015/097246, dated Mar. 18, 2016.
Kadin, Jr. et al., "Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway," Molecular Cell (2008), 30(4), pp. 393-402.
Schofield et al., "Oxygen Sensing by HIF Hydroxylases," Nature Reviews: Molecular Cell Biology (2004), 5(5), pp. 343-354.
Semenza et al., "A Nuclear Factor Induced by Hypoxia via De Novo Protein Synthesis Binds to the Human Erythropoietin Gene Enhancer at a Site Required for Transcriptional Activation," Molecular and Cellular Biology (1992), 12(12), pp. 5447-5454.
Wang et al., "Purification and Characterization of Hypoxia-inducible Factor 1," The Journal of Biological Chemistry (1995), 270(3), pp. 1230-1237.

Also Published As

Publication number Publication date
EP3275864A4 (de) 2018-08-22
JP6473519B2 (ja) 2019-02-20
JP2018510201A (ja) 2018-04-12
CN106146395B (zh) 2019-01-01
WO2016155359A1 (zh) 2016-10-06
US20180117021A1 (en) 2018-05-03
EP3275864B1 (de) 2019-08-14
EP3275864A1 (de) 2018-01-31
CN106146395A (zh) 2016-11-23

Similar Documents

Publication Publication Date Title
US8252817B2 (en) Dipyridyl-dihydropyrazolones and their use
TWI385165B (zh) 經二取代之呔猬狀途徑拮抗劑
KR101421786B1 (ko) 단백질 키나제 및 히스톤 디아세틸라제의 억제제로서 나프탈렌 카르복스아미드 유도체, 그 제조 방법 및 용도
JP5518887B2 (ja) 四置換ピリダジンヘッジホッグ経路アンタゴニスト
US8404687B2 (en) Disubstituted phthalazine hedgehog pathway antagonists
US9994566B2 (en) Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof
US10149841B2 (en) Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof
US10100051B2 (en) Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof
US12528777B2 (en) Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof
CN119350316B (zh) 一种噻唑类化合物及其制备方法、药物组合物和用途
WO2024230104A1 (zh) 多环类化合物及其用途
HK40114306A (zh) 多环类化合物及其用途
CN108084179A (zh) 一种具有螺环结构的化合物、其制备方法及应用
CN108794492A (zh) 二氮杂*并咔唑类ido抑制剂及其应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHOU, YUNLONG;CAI, SUIXIONG;WANG, GUANGFENG;AND OTHERS;REEL/FRAME:043685/0247

Effective date: 20170921

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4